Real-world evidence in the management of type 2 diabetes: switching from other DPP‑4 inhibitors to alogliptin (Vipidia®)
This promotional educational webinar has been organised and funded by Takeda UK Ltd. See bottom of page for full disclaimer.
This animation has been commissioned and funded by Boehringer Ingelheim Ltd and developed in partnership with Guidelines in Practice. Boehringer Ingelheim Ltd suggested the topic and the presenter, and carried out full medical approval on all materials to ensure compliance with regulations. The sponsorship fee included an honorarium for the ...
This formulary discussion guide was developed from content provided by Amgen Ltd in a format developed by Guidelines in Practice.
Secondary event prevention and risk stratification in patients with symptomatic peripheral arterial disease (PAD)
Information intended for healthcare professionals only. The development of this Guidelines in Practice video has been commissioned by Bayer plc. Please see the bottom of the page for full disclaimer.